<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2015.43009</article-id><article-id pub-id-type="publisher-id">HJO-15976</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20150300000_88100909.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  曲安奈德后Tenon囊下注射治疗Vogt-小柳-原田氏病黄斑部浆液性脱离
  Injection of Triamcinolone Acetonide (TA) under Tenon’s on the Macular Serous Retinal Detachment of Vogt-Koyanagi-Harada (VKH) Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>付林</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>惠玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>解放军306医院眼科，北京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>09</month><year>2015</year></pub-date><volume>04</volume><issue>03</issue><fpage>47</fpage><lpage>51</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：观察曲安奈德球后Tenon囊下注射联合全身糖皮质激素治疗Vogt-小柳-原田氏病的临床疗效。方法：经眼底荧光血管造影和频域OCT确诊的Vogt-小柳-原田氏病18例34眼，病变急性期给予行大剂量糖皮质激素冲击治疗，激素减量期间结合曲安奈德后Tenon囊下注射，时间为每月1次，20 mg/0.5 ml次，共3次。所有患者在治疗前及治疗后检查裸眼视力、最佳矫正视力、眼前节检查、眼底彩照和频域光相干断层扫描，并使用SPSS17.0 对数据进行统计学分析。结果：治疗后所有患者视力均有不同程度提高。治疗前所有患者造影出现多数针尖状高荧光点和多湖状高荧光斑，治疗6个月，32眼荧光素眼底血管造影未见异常，其平均高度为378 &#177; 234 um。治疗后其平均高度为153 &#177; 67 um，比治疗前平均下降59.5%。两组比较差异有显著统计学意义(p &lt; 0.01)。结论：曲安奈德后Tenon’s注射治疗Vogt-小柳-原田病，能够明显改善黄斑区的浆液性视网膜脱离并能减少疾病的复发。 Objectives: To observe the clinic effect of Vogt-Koyanagi- Harada (VKH) Disease by injecting triamcinolone acetonide (TA) under Tenon’s. Methods: 34 eyes of 18 consecutive patients diagnosed with acute Vogt-Koyanagi-Harada Disease by FFA and OCT. All the patients were given pmethylprednisolone combined with triamcinolone acetonide (TA) injection under Tenon’s, and the frequency is once a month, 20 mg/0.5ml every time, and it will be done totally three times. All the patients were performed no-corrected visual activity, best corrected visual activity, slit- lamp check, fundus photograph and spectral-domain optical coherence tomography (OCT) at the initial visit and 6 months after steroid treatment. All the data were analyzed by SPSS 17.0. Results: After the treatment, all the patients’ VA improved. At the initial, all eyes showed the most hyperfluorescence pinpoints and the leakage of fluorescence pooling. After treatment for 6 months, the FFA of 32 patients showed normal. The thickness of fovea was (378 &#177; 234) μm before treatment and (153 &#177; 67) μm after treatment, which decreased by 59.5% on average; there was significantly difference between the two groups (p &lt; 0.01). Conclusion: For VHK disease, the treatment of pmethylprednisolone combined with TA injection under Tenon’s can improve the macular serous retinal detachment and reduce the relapse of the disease.
    
  
 
</p></abstract><kwd-group><kwd>Vogt-小柳-原田氏病，曲安奈德，Tenon’s囊, Vogt-Koyanagi-Harada Disease</kwd><kwd> Triamcinolone Acetonide</kwd><kwd> Tenon’s Capsure</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>曲安奈德后Tenon囊下注射治疗 Vogt-小柳-原田氏病黄斑部浆液性脱离<sup> </sup></title><p>肖静，高付林，郭惠玲*</p><p>解放军306医院眼科，北京</p><p>Email: juliaoph@126.com, <sup>*</sup>guooph@126.com</p><p>收稿日期：2015年8月3日；录用日期：2015年8月20日；发布日期：2015年9月2日</p><disp-formula id="hanspub.15976-formula38"><graphic xlink:href="http://html.hanspub.org/file/1-2230067x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：观察曲安奈德球后Tenon囊下注射联合全身糖皮质激素治疗Vogt-小柳-原田氏病的临床疗效。方法：经眼底荧光血管造影和频域OCT确诊的Vogt-小柳-原田氏病18例34眼，病变急性期给予行大剂量糖皮质激素冲击治疗，激素减量期间结合曲安奈德后Tenon囊下注射，时间为每月1次，20 mg/0.5 ml次，共3次。所有患者在治疗前及治疗后检查裸眼视力、最佳矫正视力、眼前节检查、眼底彩照和频域光相干断层扫描，并使用SPSS17.0 对数据进行统计学分析。结果：治疗后所有患者视力均有不同程度提高。治疗前所有患者造影出现多数针尖状高荧光点和多湖状高荧光斑，治疗6个月，32眼荧光素眼底血管造影未见异常，其平均高度为378 &#177; 234 um。治疗后其平均高度为153 &#177; 67 um，比治疗前平均下降59.5%。两组比较差异有显著统计学意义(p &lt; 0.01)。结论：曲安奈德后Tenon’s注射治疗Vogt-小柳-原田病，能够明显改善黄斑区的浆液性视网膜脱离并能减少疾病的复发。</p><p>关键词 :Vogt-小柳-原田氏病，曲安奈德，Tenon’s囊</p><disp-formula id="hanspub.15976-formula39"><graphic xlink:href="http://html.hanspub.org/file/1-2230067x7_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>Vogt-小柳-原田氏(Vogt-Koyanagi-Harada, VKH)综合征是累及全身多系统的眼部肉芽肿性炎性疾病。眼部病变的典型表现为急性期后极部视网膜脉络膜水肿，视网膜出现浆液性渗出性脱离，引起双眼视力急剧下降[<xref ref-type="bibr" rid="hanspub.15976-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.15976-ref2">2</xref>] 。通常球周注射类固醇激素治疗葡萄膜炎的相关性黄斑水肿，其可以提高视力并且风险较小。本研究通过对曲安耐德后Tenon’s囊注射治疗Vogt-小柳-原田病，对其治疗安全性和有效性进行分析。</p></sec><sec id="s4"><title>2. 对象和方法</title><sec id="s4_1"><title>2.1. 研究对象</title><sec id="s4_1_1"><title>2.1.1. 一般资料</title><p>选择于2008年3月~2010年12月在我院眼科门诊就诊的Vogt-小柳-原田病患者18例34眼，其中男性12例23眼，女性6例11眼。年龄21~49岁(平均34岁)，发病时间3~18天。</p></sec><sec id="s4_1_2"><title>2.1.2. 病例入选标准</title><p>根据疾病发展程度，按照1999年美国洛杉矶召开的第一届Vogt-小柳-原田病国际修订的诊断标准[<xref ref-type="bibr" rid="hanspub.15976-ref3">3</xref>] ，所有患者接受治疗前均行眼科常规检查及荧光素眼底血管造影、光学相干断层扫描等检查证实为Vogt-小柳-原田病。</p></sec><sec id="s4_1_3"><title>2.1.3. 病例排除标准</title><p>1) 曾经有眼球穿通伤或眼部手术史；2) 经临床或实验室检测合并其他眼科疾病。</p></sec></sec></sec><sec id="s5"><title>3.方法</title><sec id="s5_1"><title>3.1. 糖皮质激素治疗方案</title><p>所有患者在治疗前常规进行血常规、胸部X片检查，确认无皮质激素应用禁忌后，病变急性期给予甲基强的松200 mg静滴，每3天减量40 mg，减至80 mg后改为强的松片口服，剂量为1 mg，每1~2周减量5 mg，减至30 mg/d时，持续1个月，以后每个月减量5 mg至停药，用药时程4~6个月。</p></sec><sec id="s5_2"><title>3.2. 曲安奈德给药方案</title><p>所有患者使用糖皮质激素减至30 mg/d时，行曲安奈德后部巩膜旁间隙注射，时间为每月1次，20 mg/次，共3次。注射方法：表面麻醉后，6号泪道冲洗针弯曲成弧形，患眼向鼻下方注视，在颞上方11:00钟赤道附近，紧贴巩膜进针，自外直肌及下直肌之间沿巩膜面进入赤道后部，进针深度24 mm，注射曲安奈德20 mg，注药后结膜囊涂抗生素眼膏。</p></sec><sec id="s5_3"><title>3.3. 检查项目</title><p>所有患者在治疗前及治疗后1周、1个月、3个月、6个月常规检查裸眼视力、最佳矫正视力、眼前节检查、眼底荧光血管造影和频域光相干断层扫描。所有检查由同一检查者完成，重复进行3次。</p></sec><sec id="s5_4"><title>3.4. 统计学方法</title><p>所有数据采用SPSS 13.0软件进行处理，治疗前后的视力比较采用卡方检验，治疗前后视网膜神经层厚度比较采用t检验，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s6"><title>4. 结果</title><sec id="s6_1"><title>4.1. 治疗后患者视力的比较(表1)</title><p>治疗后1周视力有所提高，35.2%的患者视力&gt;0.4；治疗后3个月70.6%患眼的视力&gt;0.4；治疗后6个月94.0%的患眼视力&gt;0.4。治疗后6个月与治疗前平均视力比较差异有统计学意义(p = 0.000)。</p></sec><sec id="s6_2"><title>4.2. 荧光素眼底血管造影检查</title><p>皮质激素治疗前，全部34眼在造影早期视网膜后极部均出现多数针尖状高荧光点和多湖状高荧光斑，伴有8眼视乳头荧光渗漏，视乳头边界欠清晰。治疗后1个月后所有患者的针尖状高荧光素和多湖状高荧光斑消失，仅有4眼仍存在轻度视乳头渗漏。治疗后3个月及6个月，32眼荧光素眼底血管造影未见异常，2眼出现视网膜色素紊乱。</p></sec><sec id="s6_3"><title>4.3. 光学相关断层图象</title><p>在皮质激素治疗前，18例34眼Vogt-小柳-原田病患者中有33眼(97.1%)黄斑中心凹处存在浆液性视网膜脱离，其平均高度为378 &#177; 234 um (图1)。皮质激素治疗后1周，33眼中有31 眼(93.9%)浆液性视网膜脱离仍然存在，但是视网膜下液明显吸收(图2)，其平均高度为153 &#177; 67 um，比治疗前平均下</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The distribution of vision activity before and after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >时间</th><th align="center" valign="middle"  colspan="2"  >视力</th></tr></thead><tr><td align="center" valign="middle" >&lt;0.4</td><td align="center" valign="middle" >&gt;0.4</td></tr><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >30 (88.2)</td><td align="center" valign="middle" >4 (11.8)</td></tr><tr><td align="center" valign="middle" >治疗后1周</td><td align="center" valign="middle" >22 (64.8)</td><td align="center" valign="middle" >12 (35.2)</td></tr><tr><td align="center" valign="middle" >治疗后1月</td><td align="center" valign="middle" >14 (41.5)</td><td align="center" valign="middle" >20 (58.5)</td></tr><tr><td align="center" valign="middle" >治疗后3月</td><td align="center" valign="middle" >10 (29.4)</td><td align="center" valign="middle" >24 (70.6)</td></tr><tr><td align="center" valign="middle" >治疗后6个月</td><td align="center" valign="middle" >2 (6.0)</td><td align="center" valign="middle" >32 (94.0)</td></tr></tbody></table></table-wrap><p>表1. 治疗前后视力分布表</p><p>图1. 治疗前黄斑区OCT图像</p><p>图2. 治疗后黄斑区OCT图像</p><p>降59.5 %。治疗前后比较差异有显著统计学意义(t = 5.310, p = 0.000)。治疗后1个月34眼浆液性视网膜脱离全部消失。治疗后3个月及6个月，黄斑中心凹OCT图像与正常人图像基本一致。</p></sec></sec><sec id="s7"><title>5. 讨论</title><p>Vogt-小柳-原田病眼部主要表现为肉芽肿性全葡萄膜炎，VKH急性葡萄膜炎期眼底主要病理改变为双侧弥漫性脉络膜炎，并继发RPE损害。PRE结构及功能失代偿，屏障功能破坏，导致脉络膜炎性产物穿透RPE渗入视网膜神经上皮下，进而引起后极部视网膜神经上皮不同程度、不同范围脱离。</p><p>曲安奈德是一种非水溶性、人工合成的糖皮质激素，具有很强的抗炎作用。近年来国内外报道玻璃体腔注射曲安奈德治疗各种原因引起的黄斑水肿，其中也包括葡萄膜炎[<xref ref-type="bibr" rid="hanspub.15976-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.15976-ref5">5</xref>] 。有大量研究报道通过玻璃体腔内注射曲安奈德来治疗VHK综合征的急性和慢性炎症症状取得较好的效果[<xref ref-type="bibr" rid="hanspub.15976-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.15976-ref7">7</xref>] 。但是，玻璃体腔注射可以引起一系列并发症如眼内压升高、白内障和眼内炎的风险。Perente等[<xref ref-type="bibr" rid="hanspub.15976-ref8">8</xref>] 推荐曲安奈德在Tenon’s囊下注射代替玻璃体腔注射对于治疗难以控制的葡萄膜炎取得较好的效果。与玻璃体腔注射相比，后Tenon’s囊下注射可以通过巩膜渗透到眼内。动物研究表明[<xref ref-type="bibr" rid="hanspub.15976-ref9">9</xref>] 后Tenon囊下注射曲安奈德后，药物能够在玻璃体腔达到有效的治疗质量浓度，并维持一定时间。本研究中通过大剂量的糖皮质激素冲击治疗后，在激素减量期间，结合曲安奈德球旁注射，可以控制眼部的炎症症状，减少疾病复发的几率，缩短糖皮质激素的使用周期，显著提高该疾病的治疗效果。</p><p>全身大剂量糖皮质激素联合应用曲安奈德后Tenon’s注射治疗Vogt-小柳-原田病，可促进黄斑区视网膜下积液迅速吸收，使视网膜脱离复位，视力提高并能显著减轻眼前节葡萄膜炎。FFA和OCT行病情随访观察，均显示眼底病变的减轻趋势，该治疗方法有助于缩短Vogt-小柳-原田病疾病治疗时间并能减少疾病的复发。</p></sec><sec id="s8"><title>文章引用</title><p>肖 静,高付林,郭惠玲. 曲安奈德后Tenon囊下注射治疗Vogt-小柳-原田氏病黄斑部浆液性脱离Injection of Triamcinolone Acetonide (TA) under Tenon’s on the Macular Serous Retinal Detachment of Vogt-Koyanagi-Harada (VKH) Disease[J]. 眼科学, 2015, 04(03): 47-51. http://dx.doi.org/10.12677/HJO.2015.43009</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.15976-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Read, R., Yu, F., Accorinti, M., Bodaghi, B., Chee, S.-P., Fardeau, C., et al. (2006) Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. American Journal of Ophthalmology, 142,119-124. &lt;br&gt;http://dx.doi.org/10.1016/j.ajo.2006.02.049</mixed-citation></ref><ref id="hanspub.15976-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">杨培增 (2004) 临床葡萄膜炎. 人民卫生出版社, 北京, 293.</mixed-citation></ref><ref id="hanspub.15976-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Rao, N.A., Sukavatchsrin, S. and Tsai, J.H. (2007) Vogt-Koyanagi-Harada disease diagnostic criteria. International Ophthalmology, 27, 195-199. &lt;br&gt;http://dx.doi.org/10.1007/s10792-006-9021-x</mixed-citation></ref><ref id="hanspub.15976-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Durrani, O.M., Meads, C.A. and Murray, P.I. (2004) Uveitis: A potentially blinding disease. Ophthalmologica, 218, 223-236. &lt;br&gt;http://dx.doi.org/10.1159/000078612</mixed-citation></ref><ref id="hanspub.15976-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Martidis, A., Duker, J.S., Greenbery, P.B., Rogers, A.H., Puliafito, C.A., Reichel, E. and Baumal, C. (2002) Intravitreal triamcinolone forefractory diabetic macular edema. Ophthalmology, 109, 920-927.  
&lt;br&gt;http://dx.doi.org/10.1016/S0161-6420(02)00975-2</mixed-citation></ref><ref id="hanspub.15976-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Andrade, R., Muccioli, C. and Farah, M. (2004) Intravi-treal triamcinolone acetonide injection in the treatment of Vogt- Koyanagi-Harada syndrome. Arquivos Brasileiros de Oftalmologia, 67, 401-406.  
&lt;br&gt;http://dx.doi.org/10.1590/S0004-27492004000300005</mixed-citation></ref><ref id="hanspub.15976-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Couch, S.M. and Bakri, S.J. (2009) Intravitreal triam-cinolone for intraocular inﬂammation and associated macular edema. Clinical Ophthalmology, 3, 41-47.</mixed-citation></ref><ref id="hanspub.15976-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Perente, I., Utice, C.A., Cakir, H., Kaya, V., Tutkun, I.T. and Yilmaz, O.F. (2009) Management of ocular complications of Vogt-Koyanagi-Harada syndrome. International Ophthalmology, 29, 33-37.  
&lt;br&gt;http://dx.doi.org/10.1007/s10792-007-9159-1</mixed-citation></ref><ref id="hanspub.15976-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">关红英, 李双农 (2009) 后Tenon囊下注射曲安奈德后玻璃体腔内药物质量浓度的测定. 眼科研究, 6, 507-510.</mixed-citation></ref></ref-list></back></article>